Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

• Biological: Multivalent
  
  Pneumococcal conjugate vaccine
• Biological: Prevnar 13
  
  Pneumococcal conjugate vaccine
• Biological: PPSV23
  
  Pneumococcal polysaccharide vaccine
  Other Name: Pneumovax 23
• Other: Saline
  
  Placebo

• Experimental: Multivalent
  
  Pneumococcal conjugate vaccine
  Interventions:
  

  • Biological: Multivalent
  • Other: Saline
• Active Comparator: Control
  
  Prevnar 13 and PPSV23
  Interventions:
  

  • Biological: Prevnar 13
  • Biological: PPSV23

Inclusion Criteria:

1. Male or female adults >/= 60 to
2. Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.
3. Female subjects who are not of childbearing potential.

Exclusion Criteria:

1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
2. History of microbiologically proven invasive disease caused by S pneumoniae.
3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.